Tonix Pharmaceuticals Holding Corp. reported financial results for the fourth quarter and full year ended December 31, 2025, highlighting the successful U.S. launch of TONMYA, the first new medicine approved for fibromyalgia in more than 15 years. The product, approved by the U.S. Food and Drug Administration in August 2025, became commercially available by prescription on November 17, 2025, with early launch metrics indicating growing prescriber uptake. More than 1,500 healthcare providers have prescribed the therapy, and approximately 2,500 patients have initiated treatment.
The importance of this development lies in addressing a significant unmet medical need for millions of fibromyalgia patients who have had limited treatment options for over a decade and a half. Fibromyalgia affects approximately 4 million adults in the United States, causing widespread pain, fatigue, and cognitive difficulties. The availability of a new therapeutic option represents a meaningful advancement in patient care and treatment possibilities.
Tonix also advanced several pipeline programs during the year, including in-licensing TNX-4800 for the seasonal prevention of Lyme disease and receiving Investigational New Drug clearance for the HORIZON Phase 2 study of TNX-102 SL for major depressive disorder. The company progressed development across its immunology and rare disease programs while ending the year with approximately $207.6 million in cash and cash equivalents to support operations into the first quarter of 2027.
The company's broader pipeline includes multiple investigational programs with potential implications across several therapeutic areas. Tonix is maximizing the science behind TONMYA in Phase 2 clinical trials to evaluate its potential in major depressive disorder and acute stress disorder. The CNS portfolio also includes TNX-2900, which is Phase 2 ready for the treatment of Prader-Willi syndrome, a rare disease. Immunology programs include monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
For investors and stakeholders seeking additional information, the latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP. The financial results and corporate developments have broader implications for the biotechnology sector, demonstrating how commercial-stage companies can balance product launches with pipeline advancement while maintaining financial stability. The successful launch of TONMYA validates Tonix's commercial capabilities and provides a foundation for future growth across its CNS and immunology portfolio.
